Page 1 of 1
 
 **Please be sure that you do NOT include any proprietary company information in the responses below**   

 
 
*
 
   
 
*
 
   
 
*
Please identify the level of experience with each capability
 
    
Viral   
Bacterial   
Biological   
Protection against aerosolized route of exposure   
   
 
*
 
   
 
 
    
animal models of viral toxin and pathogenesis (multiple routs of exposure)   
animal models of bacterial toxin and pathogenesis (multiple routs of exposure)   
animal models of biological toxin and pathogenesis (multiple routs of exposure)   
assays   
diagnostic technologies   
other platform technologies   
CLIA certification   
GLP/cGMP   
   
 
*
 
   
 
 
    
diagnosis of exposure to traditional and emerging chemical nerve agent threats   
prophylaxis of exposure to traditional and emerging chemical nerve agent threats   
treatment of exposure to traditional and emerging chemical nerve agent threats   
diagnosis of exposure to other emerging chemical threats other than nerve agents   
prophylaxis of exposure to other emerging chemical threats other than nerve agents   
treatment of exposure to other emerging chemical threats other than nerve agents   
   
 
*
 
   
 
 
    
diagnosis of exposure to radiological and nuclear threats   
prophylaxis of exposure to radiological and nuclear threats   
treatment of exposure to radiological and nuclear threats   
diagnosis of exposure to Acute Radiation Syndrome   
prophylaxis of exposure to Acute Radiation Syndrome   
treatment of exposure to Acute Radiation Syndrome   
   
 
*
 
   
 
*
Please specify the level of experience with each capability
 
    
for single drug administration   
for dual drug administration   
for multi-drug (>2) administration   
   
 
*
 
   
 
*
Please identify the level of experience with each capability
 
    
Manufacture and test identified protective molecule(s) and target molecules(s)   
Multiple scalable, flexible manufacturing platforms encompassing a diverse array of manufacturing systems (e.g. insect, mammalian, live viral, plant, E. coli, yeast, etc.) for use in appropriate animal model(s) and in Phase I   
Formulation development   
   
 
*
 
   
 
*
Please specify the level of experience with each capability
 
    
Experience with the FDA Animal Rule   
Utilize adjuvants and excipients supporting the ability to develop up to 300,000 equivalent doses within 60 days at clinical quality   
   
 
*
 
   
 
*
Please specify the level of experience with each capability
 
    
Organisms that circulate freely and at relatively high numbers at or near the onset of symptoms   
Organisms that circulate in low numbers early in infection but then integrate with host cells   
Organisms that have significant genomic diversity from strain to strain   
Non-BW agents such as toxins, chemical agents, radiological agents that do not replicate and require low quantities to cause illness    
   
 
*
 
   
 
*
Please specify the level of experience with each capability
 
    
Experience supporting the Defense Biological Products Assurance Office (formally the Critical Reagents Program)   
Experience with DoD Advanced Development and Manufacturing contractors   
   
 
*
 
   
 
Please describe capabilities in box below and be sure to include examples of each.
 
   
 
 
 
 Done